Mostrar el registro sencillo del ítem
Prostate cancer: ESMO consensus conference guidelines 2012
dc.creator | Horwich, A. | en |
dc.creator | Hugosson, J. | en |
dc.creator | de reijke, T. | en |
dc.creator | Wiegel, T. | en |
dc.creator | Fizazi, K. | en |
dc.creator | Kataja, V. | en |
dc.creator | Parker, C. | en |
dc.creator | Bellmunt, J. | en |
dc.creator | Berthold, D. | en |
dc.creator | Bill-axelson, A. | en |
dc.creator | Carlsson, S. | en |
dc.creator | Daugaard, G. | en |
dc.creator | De meerleer, G. | en |
dc.creator | De reijke, T. | en |
dc.creator | Dearnaley, D. | en |
dc.creator | Fonteyne, V. | en |
dc.creator | Gillessen, S. | en |
dc.creator | Heinrich, D. | en |
dc.creator | Kwiatkowski, M. | en |
dc.creator | Nilsson, S. | en |
dc.creator | Padhani, A. | en |
dc.creator | Papandreou, C. | en |
dc.creator | Roobol, M. | en |
dc.creator | Sella, A. | en |
dc.creator | Valdagni, R. | en |
dc.creator | Van der kwast, T. | en |
dc.creator | Verhagen, P. | en |
dc.date.accessioned | 2015-11-23T10:30:09Z | |
dc.date.available | 2015-11-23T10:30:09Z | |
dc.date.issued | 2013 | |
dc.identifier | 10.1093/annonc/mds624 | |
dc.identifier.issn | 9237534 | |
dc.identifier.uri | http://hdl.handle.net/11615/28504 | |
dc.description.abstract | The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological aspects. Before the conference, the expert panel prepared clinically relevant questions about prostate cancer in four areas for discussion as follows: diagnosis and staging, management of early localized disease, management of advanced localized disease and systemic disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84877101072&partnerID=40&md5=a249b49ecab845631e2ba58d9e91c8ff | |
dc.subject | Consensus | en |
dc.subject | ESMO | en |
dc.subject | Prostate cancer | en |
dc.subject | abiraterone | en |
dc.subject | abiraterone acetate | en |
dc.subject | antiandrogen | en |
dc.subject | bicalutamide | en |
dc.subject | cabazitaxel | en |
dc.subject | clodronic acid | en |
dc.subject | denosumab | en |
dc.subject | docetaxel | en |
dc.subject | enzalutamide | en |
dc.subject | gonadorelin agonist | en |
dc.subject | gonadorelin antagonist | en |
dc.subject | gonadorelin derivative | en |
dc.subject | pamidronic acid | en |
dc.subject | placebo | en |
dc.subject | prednisone | en |
dc.subject | prostate specific antigen | en |
dc.subject | radioisotope | en |
dc.subject | radium 223 | en |
dc.subject | sipuleucel T | en |
dc.subject | unclassified drug | en |
dc.subject | zoledronic acid | en |
dc.subject | age | en |
dc.subject | androgen deprivation therapy | en |
dc.subject | article | en |
dc.subject | bone metastasis | en |
dc.subject | brachytherapy | en |
dc.subject | cancer diagnosis | en |
dc.subject | cancer hormone therapy | en |
dc.subject | cancer localization | en |
dc.subject | cancer screening | en |
dc.subject | cancer staging | en |
dc.subject | castration resistant prostate cancer | en |
dc.subject | clinical effectiveness | en |
dc.subject | comorbidity | en |
dc.subject | digital rectal examination | en |
dc.subject | drug efficacy | en |
dc.subject | drug treatment failure | en |
dc.subject | European Society for Medical Oncology | en |
dc.subject | external beam radiotherapy | en |
dc.subject | family history | en |
dc.subject | human | en |
dc.subject | hypocalcemia | en |
dc.subject | image guided radiotherapy | en |
dc.subject | intensity modulated radiation therapy | en |
dc.subject | jaw osteonecrosis | en |
dc.subject | lymph node dissection | en |
dc.subject | medical society | en |
dc.subject | metastatic hormone naive prostate cancer | en |
dc.subject | nomogram | en |
dc.subject | pelvis lymph node | en |
dc.subject | practice guideline | en |
dc.subject | priority journal | en |
dc.subject | prostate biopsy | en |
dc.subject | prostatectomy | en |
dc.subject | radiation dose | en |
dc.subject | Switzerland | en |
dc.subject | symptom | en |
dc.subject | transrectal ultrasonography | en |
dc.subject | Antineoplastic Agents, Hormonal | en |
dc.subject | Humans | en |
dc.subject | Lymph Nodes | en |
dc.subject | Male | en |
dc.subject | Prostate-Specific Antigen | en |
dc.subject | Prostatic Neoplasms | en |
dc.title | Prostate cancer: ESMO consensus conference guidelines 2012 | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |